Hugel Showcases Achievements of Botulinum Toxin "Letybo" Beyond the Great Wall

Achieving Over 15% Market Share in the Chinese Botulinum Toxin Market

Medical aesthetics company Hugel announced on October 22 that it is celebrating the fifth anniversary of its botulinum toxin product "Letybo" entering the Chinese market.

The large-scale brand event held by Hugel on the 21st at the Commune by the Great Wall Hotel in Beijing, China. Photo by Hugel

In 2020, Hugel became the first and only Korean company to enter the Chinese toxin market. Since then, leveraging its partnership with local company Sihuan Pharmaceutical, Hugel has expanded its distribution network by emphasizing Letybo’s proven efficacy and safety.

Letybo is now available in more than 370 regions across China and is supplied to approximately 6,800 medical aesthetic institutions, which accounts for about 85% of all registered medical aesthetic institutions in China, according to statistics from the Chinese Association of Plastics and Aesthetics. Based on this growth, Letybo has captured over 15% market share in China, and its 50-unit product is estimated to be the market leader.

China is the world’s second-largest botulinum toxin market after the United States, and it is expected to grow at an average annual rate of about 20% through 2029. Given its large market size and stringent regulatory requirements, China is considered a key market that determines the growth and profitability of global toxin companies. Currently, only six toxin products are approved in China.

To mark its fifth anniversary in China, Hugel held a large-scale brand event on October 21 at the Commune by the Great Wall Hotel in Beijing. The event, designed to share Letybo’s growth journey and future vision, was attended by more than 250 people, including key figures in China and representatives from the Chinese Association of Plastics and Aesthetics.

During the academic session, Li Qin, Chief Director of Esther Group, a major Chinese medical aesthetics group, and Kim Hyunok, Director of Korea’s Klim Clinic, participated and shared clinical insights focusing on Letybo treatment trends in China and global application cases.

In the panel discussion chaired by Professor Choi Haiyan of Tongji Hospital, Shanghai Tongji University, there was an in-depth discussion on the diagnosis and future direction of the global aesthetics market, as well as the evolving roles of medical professionals. The panelists agreed that the Korean and Chinese medical aesthetics industries must transition from simple price competition to a "value-driven market" based on differentiated technology and services.

The gala dinner, which concluded the event, was held against the backdrop of the actual Great Wall of China. The concept of "infinity" symbolized by the Great Wall was reflected throughout the event, metaphorically expressing Letybo’s relentless spirit of challenge and commitment to clinical exploration in the Chinese market.

Ji Seungwook, Executive Vice President and Head of Business at Hugel, said, "As the only Korean toxin company in China, Hugel has strengthened trust and its position in the market through genuine product certification activities and its own academic programs. This event has further solidified our commitment to stronger cooperation with Sihuan Pharmaceutical, and we will continue to cement our status as the leading K-toxin brand."

This content was produced with the assistance of AI translation services.